Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05514548 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

A Phase 2 study of Diabetic Kidney Disease, sponsored by Inversago Pharma.

Completed
Registry status
Phase 2
Development phase
265
Enrollment target
20
Study locations

NCT05514548 is a Phase 2 study of Diabetic Kidney Disease that has completed, run by Inversago Pharma. The registered enrollment target is 265 participants, below the 5,178-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05514548, a Phase 2 study of Diabetic Kidney Disease, has completed, sponsored by Inversago Pharma.

COMPLETED
Registry status
Phase 2
Development phase
265 participants
Enrollment target
20
Study locations

Study Summary

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

Conditions Studied

Diabetic Kidney Disease

Interventions

  • DRUG Placebo
  • DRUG INV-202

Study Locations (20)

California

  • National Institute of Clinical Research, Inc. - Garden Grove
  • National Institute of Clinical Research, Inc - Pomona - Pomona
  • Central Coast Nephrology - Salinas
  • North American Research Institute - San Dimas
  • National Institute of Clinical Research, Inc - Upland - Upland

Florida

  • Research Physicians Network Alliance - Boca Raton
  • ALL Medical Research, LLC - Cooper City
  • South Florida Research Institute - Lauderdale Lakes

Texas

  • North Texas Endocrine Center - Dallas
  • Biopharma Informatic, LLC - Houston
  • Linq Research, LLC - Pearland

Georgia

  • Endocrine Research Solutions, Inc. - Roswell

Illinois

  • Research by Design, LLC - Chicago

Maryland

  • Endocrine and metabolic Consultants - Rockville

Missouri

  • Clinical Research Consultants, LLC - Kansas City

Nevada

  • Palm Research Center, Inc - Las Vegas

Trial Details

FieldValue
Enrollment Target 265 participants
Start Date 2022-10-19
Est. Completion 2024-09-03
Phase Phase 2

Sponsor

Inversago Pharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05514548

The ClinicalTrials.gov registry entry for NCT05514548 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,178-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (95% lower). The listed sponsor is Inversago Pharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05514548 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT05514548 about?

NCT05514548 is a clinical study titled "Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease". The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

What is the current status of trial NCT05514548?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2022-10-19. Estimated completion is 2024-09-03.

What conditions does trial NCT05514548 study?

This clinical trial studies the following conditions: Diabetic Kidney Disease.

What interventions are being tested in trial NCT05514548?

The interventions under investigation include: Placebo (DRUG), INV-202 (DRUG).

Who is sponsoring clinical trial NCT05514548?

This trial is sponsored by Inversago Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05514548 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Kidney Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.